N-(2-(3-(4-(1-methyl-1H-pyrazol-4-yl)benzyl)-1H-indazol-5-ylamino)ethyl)acetamide

ID: ALA3775578

Chembl Id: CHEMBL3775578

PubChem CID: 118959880

Max Phase: Preclinical

Molecular Formula: C22H24N6O

Molecular Weight: 388.48

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)NCCNc1ccc2[nH]nc(Cc3ccc(-c4cnn(C)c4)cc3)c2c1

Standard InChI:  InChI=1S/C22H24N6O/c1-15(29)23-9-10-24-19-7-8-21-20(12-19)22(27-26-21)11-16-3-5-17(6-4-16)18-13-25-28(2)14-18/h3-8,12-14,24H,9-11H2,1-2H3,(H,23,29)(H,26,27)

Standard InChI Key:  CISPMBXZQNYLKC-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA3775578

    ---

Associated Targets(Human)

CDK8 Tchem CDK8/Cyclin C (1054 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CDK8 Tchem Cell division protein kinase 8 (1536 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Liver microsome (8277 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Liver microsome (4459 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 388.48Molecular Weight (Monoisotopic): 388.2012AlogP: 3.10#Rotatable Bonds: 7
Polar Surface Area: 87.63Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.92CX LogP: 1.83CX LogD: 1.83
Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.42Np Likeness Score: -1.66

References

1. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.,  26  (5): [PMID:26852363] [10.1016/j.bmcl.2016.01.062]

Source